Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
05 sept. 2023 07h30 HE
|
Wave Life Sciences USA, Inc.
WVE-006 is the first-ever RNA editing program to enter clinical development and is designed to restore production and circulation of functional, wild-type alpha-1 antitrypsin (AAT) protein and reduce...
Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
03 août 2023 07h30 HE
|
Wave Life Sciences USA, Inc.
Preparing for imminent submission of clinical trial applications (CTAs) for GalNAc-conjugated AATD candidate (WVE-006), the industry’s first RNA editing clinical candidate Novel DMD therapeutic...
Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023
27 juil. 2023 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling...
Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes
26 juin 2023 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling...
Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
23 mai 2023 07h30 HE
|
Wave Life Sciences USA, Inc.
Potent and durable target engagement observed across cohorts, including with 10 mg doses administered every 12 weeks which were also generally safe and well-tolerated WVE-004 did not show clinical...
Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual Meeting
16 mai 2023 08h30 HE
|
Wave Life Sciences USA, Inc.
Presentations include new data showing WVE-006 improved markers of liver disease in mice; WVE-006 is a first-in-class RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD) which is...
Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update
03 mai 2023 07h30 HE
|
Wave Life Sciences USA, Inc.
Emerging leader in RNA medicines with multi-modal discovery and development platform and first-in-class RNA editing programs Rapidly advancing toward 2023 CTA submissions and first-in-human...
Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023
26 avr. 2023 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry
20 avr. 2023 08h30 HE
|
Wave Life Sciences USA, Inc.
Published preclinical data demonstrate unprecedented Ago2 loading following administration of single subcutaneous siRNA dose, leading to improved potency and durability in vivo versus comparator siRNA...
Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days
29 mars 2023 08h00 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...